Citi lowered the firm’s price target on Sight Sciences (SGHT) to $4 from $4.50 and keeps a Neutral rating on the shares. The firm is cautious on medical technology entering the Q3 earnings season. Citi believes the outcome of the Section 232 investigation into medical equipment and devices will take time.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences Amends Loan Agreement with Hercules
- Sight Sciences announces publication of results on OMNI Surgical System
- Sight Sciences: Balancing Resilience in Glaucoma Market with Reimbursement Challenges – Hold Rating Justified
- Needham medtech & diagnostics analysts hold analyst/industry conference call
- Sight Sciences OMNI Surgical System to be included in UnitedHealthcare coverage